findmyKOL

Suzanne Lentzsch, MD

Enriched profile

Professor of Medicine; Director, Multiple Myeloma and Amyloidosis Program/Service · Columbia University Irving Medical Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyMedical OncologyFocusMultiple Myeloma Research and Treatments+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2014–2026

Suzanne Lentzsch is Professor of Medicine; Director, Multiple Myeloma and Amyloidosis Program/Service at Columbia University Irving Medical Center. OpenAlex indexes 512 publications with 18,147 citations (h-index 59); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.

Data verified 17 Aug 2026

Overview

Updated 16 Oct 2026

Suzanne Lentzsch, MD, is Professor of Medicine at Columbia University Irving Medical Center / NewYork-Presbyterian Hospital. The public record shows 512 publications with 18,147 citations (h-index 59), centered on Multiple Myeloma Research and Treatments, Amyloidosis: Diagnosis, Treatment, Outcomes, Protein Degradation and Inhibitors. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 16 companies, 4 NIH-funded awards (2014–2026).

  • Most recent indexed publication: 2026 · Blood
  • Top research focus: Multiple Myeloma Research and Treatments
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 16 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Myeloma5 trialsAmyloidosis1 trialImmunoglobulin Light-chain Amyloidosis1 trialSmoldering Multiple Myeloma1 trialLeukemia (AML/ALL/CML/CLL)

Research focus

OpenAlex concept fingerprint
Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, OutcomesProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisChronic Lymphocytic Leukemia Research

Drugs & molecules

across trials, industry payments and publications
Darzalexgeneric · DaratumumabClinical trials—Industry payments5Publications2Elrexfiogeneric · ElranatamabClinical trials—Industry payments6Publications1Talveygeneric · TalquetamabClinical trials—Industry payments1Publications1Sarclisageneric · IsatuximabClinical trials—Industry payments16Publications—Tecvayligeneric · TeclistamabClinical trials—Industry payments9Publications—Carvyktigeneric · Ciltacabtagene autoleucelClinical trials—Industry payments8Publications—Blenrepgeneric · Belantamab mafodotinClinical trials—Industry payments2Publications—Ninlarogeneric · IxazomibClinical trials—Industry payments2Publications—Xpoviogeneric · SelinexorClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments49Genzyme CorporationClinical trials—Industry payments22E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments18GlaxoSmithKline, LLC.Clinical trials—Industry payments14Janssen Biotech, Inc.Clinical trials—Industry payments13Janssen Research & Development, LLCClinical trials—Industry payments13Pfizer Inc.Clinical trials—Industry payments8Kite Pharma, Inc.Clinical trials—Industry payments7AstraZeneca Pharmaceuticals LPClinical trials—Industry payments6Celgene CorporationClinical trials—Industry payments6Adaptive Biotechnologies CorporationClinical trials—Industry payments4Legend Biotech USA Inc.Clinical trials—Industry payments3Alexion Pharmaceuticals, Inc.Clinical trials—Industry payments2Columbia UniversityClinical trials2Industry payments—Karyopharm Therapeutics Inc.Clinical trials—Industry payments2Sanofi Us Services Inc.Clinical trials—Industry payments2Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments2Eastern Cooperative Oncology GroupClinical trials1Industry payments—Immune ControlClinical trials1Industry payments—Suzanne Lentzsch, MDClinical trials1Industry payments—Tufts Medical CenterClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
512publications

Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.

18,147citations

Total citations across indexed works.

59h-index

Hirsch index (OpenAlex). i10-index 171.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials ↓
16companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 2014–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

All 6 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 46 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

Updated 16 Oct 2026

4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:

All 17 award records: search, sort and filter.Explore →

Congress activity

Updated 16 Oct 2026

118 congress contributions (2005–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:

All 118 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 22 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    Article3,051 citations2016
    doi.org ↗
  2. 02
    Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    Article907 citations2001
    doi.org ↗
  3. 03
    Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
    Article724 citations2011
    doi.org ↗
  4. 04
    IMWG consensus on risk stratification in multiple myeloma
    Article601 citations2013
    doi.org ↗
  5. 05
    Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
    Article555 citations2001
    doi.org ↗
All 512 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/suzanne-lentzsch-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • ResearchGate

    researchgate.net/profile/Suzanne-Lentzsch-3

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/SLentzsch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • LinkedIn

    linkedin.com/in/suzanne-lentzsch-71576752

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Other

    bloodcancerunited.org/resources/blog/champions-myeloma-research-part-2-conversation-suzanne-lentzsch-md-phd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗
  • Other

    myelomasociety.org/officers/suzanne-lentzsch-md-phd

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Humboldt University of Berlin (Charité), Germany

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
  • PhD

    Humboldt University of Berlin, Germany

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
  • Board certified

    Medical Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗

Editorial & leadership roles

journal and society appointments
  • Co-Chair

    NCI Myeloma Steering Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
  • Board Member

    International Myeloma Society

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
  • Co-Chair

    Career Development Committee, International Myeloma Society

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
  • Scientific Advisory Board Member

    Multiple Myeloma Research Foundation

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →themmrf.org ↗
  • SWOG Myeloma Committee Member; SWOG Study Coordinator
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
  • Committee Member

    International Myeloma Foundation Black Swan Research Initiative

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
  • Member

    ASH Scientific Committee for Plasma Cell Neoplasia

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →themmrf.org ↗
  • Member

    ASCO Scientific Program Committee (Hematologic Malignancies-Plasma Cell Dyscrasia)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →themmrf.org ↗
  • Associate Editor

    Journal of Clinical Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
  • Editorial Board Member

    Blood Cancer Discovery

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.